Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: Pooled data from three placebo-controlled, fixed-dose crossover studies

European Urology, Supplement

Volumn 1, Issue 3, 2002, Pages 12-20

  Stief, C ^a   Padley, R J ^b   Perdok, R J ^b   Sleep, D J ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Apomorphine SL; Cross study review; Erectile dysfunction

Indexed keywords

APOMORPHINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; ORGASM; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

EID: 0036590115     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00009-X     Document Type: Article

References (25)

1. NIH Consensus Conference on Impotence. JAMA 1993;270:83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
3. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the MMAS. J Urol 2000;163:460-3.
4. Blanker MH, Bosch RJLH, Groeneveld FPMJ, Bohnen AM, Prins AD, Thomas S, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: Prevalence, concern, and relation to sexual activity. Urology 2001;57:763-8.
5. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the Cologne Male Survey. Int J Impot Res 2000;12:305-11.
6. Chew KK, Stuckey BGA, Thompson PL. Erectile dysfunction, sildenafil, and cardiovascular risk. Med J Aust 2000;172:279-83.
7. Gregoire A. A new treatment for erectile impotence. Br J Psychiatr 1992;160:315-26.
8. World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societé Internationale d'Urologie (SIU). In: Proceedings of the First International Consultation on Erectile Dysfunction. Paris. 1-3 July 1999.
9. Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11:59-74.
10. Witt DK. Yohimbine for erectile dysfunction. J Fam Pract 1998;46: 282-3.
11. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159:433-6.
12. Padma-Nathan H, Shabsigh R. Sildenafil citrate (Viagra®): A review. AUA Update Series, Vol. XVIII, lesson 35. Houston (TX): American Urological Association, 2000.
13. Steers WD. Viagra - after one year. Urology 1999;54:12-7.
14. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 62:722-5.
15. Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, Russell RO, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:278-82.
16. Heaton JPW, Morales A, Adams MA, Johnston B, El-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:200-6.
17. Morales A. Apomorphine to Uprima®: The development of a practical erectogenic drug, a personal perspective. Int J Impot Res 2001; 13(Suppl 3):S29-34.
18. Dula E, Keating W, Siami PF, Edmonds A, O'Neil J, Butler S and the Apomorphine Study Group. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology 2000;56:130-5.
19. Dula E, Bukofzer S, Perdok R, George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction (ED). Eur Urol 2001;39:558-64.
20. Heaton JPW. Apomorphine: An update of clinical trials. Int J Impot Res 2000;12(Suppl 4):S67-73.
21. Mulhall JP, Bukofzer S, Edmonds AL, George M and the Apomorphine Study Group. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clin Ther 2001;23:1260-71.
22. Hatzichristou D, Saenz de Tejada I, Sleep DJ, Perdok R. Time to erection with Uprima® (apomorphine SL) 2 and 3 mg in men with erectile dysfunction (ED). Int J Impot Res 2002;13(Suppl 4):S50.A140.
23. Ralph DJ, Sleep DJ, Perdok RJ, Padley RJ. Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: A cross-study analysis of phase II and phase III studies. Eur Urol Suppl 2002;1(3):21-7.
24. Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima®). Int J Impot Res 2001;13(Suppl 3):S40-4.
25. Adams M, Perdok RJ, Padley RJ, Sleep DJ. Safety and tolerability of apomorphine SL in men with cardiovascular disorders. Eur Urol Suppl 2002;1(3):28-32.